Quarterly report pursuant to Section 13 or 15(d)

REVENUES - Disaggregated (Details)

v3.23.2
REVENUES - Disaggregated (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation of Revenue [Line Items]        
Total revenues $ 26,886 $ 29,819 $ 52,956 $ 46,554
Gross product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 33,456 26,427 66,654 49,045
Discounts and allowances        
Disaggregation of Revenue [Line Items]        
Total revenues (9,575) (7,877) (19,028) (14,298)
Product sales, net        
Disaggregation of Revenue [Line Items]        
Total revenues 23,881 18,550 47,626 34,747
License revenues        
Disaggregation of Revenue [Line Items]        
Total revenues   2,337   2,545
Development milestones        
Disaggregation of Revenue [Line Items]        
Total revenues   5,000   5,000
Royalty, delivery of drug supplies and others        
Disaggregation of Revenue [Line Items]        
Total revenues 2,005 3,932 4,330 4,262
Contract revenues from collaborations        
Disaggregation of Revenue [Line Items]        
Total revenues 2,005 $ 11,269 4,330 $ 11,807
Government contract        
Disaggregation of Revenue [Line Items]        
Total revenues $ 1,000   $ 1,000